2023 World Conference on Lung Cancer (Posters)-EP08.02. Real-World Disease-Free Survival (DFS) in Non-metastatic Non-small Cell Lung Cancer (NSCLC): A German I-O Optimise Analysis

EP08.02. Real-World Disease-Free Survival (DFS) in Non-metastatic Non-small Cell Lung Cancer (NSCLC): A German I-O Optimise Analysis - PDF(Slides)

Back to course

Pdf Summary

This study analyzed real-world data from the Versorgungsforschung in der Onkologie database (VONKOdb) to assess disease-free survival (DFS) in patients with non-metastatic non-small cell lung cancer (NSCLC) who received surgery plus (neo)adjuvant or perioperative systemic anticancer therapy (SACT). The study aimed to provide a pre-immunotherapy baseline to compare with future outcomes.<br /><br />The analysis included 2,112 patients with stage I to IIIA NSCLC who were treated with surgery plus (neo)adjuvant or perioperative SACT. The majority of patients (84%) received surgery plus adjuvant SACT and radiotherapy (RT), with stage II and IIIA being the most common stages at diagnosis. The DFS ranged from 28.4-55.5 months in patients receiving adjuvant SACT and RT, and from 18.3-54.5 months in patients receiving neoadjuvant SACT and RT or perioperative SACT. <br /><br />The study found that patients with stage I NSCLC had a lower incidence compared to patients with stage II and IIIA NSCLC. The results suggest the need for practice changes and a better understanding of which patients require additional systemic treatment with surgery. <br /><br />Overall, the study provides a useful baseline for future comparisons in patient management and clinical outcomes. However, there were limitations, including the absence of information on planned treatment, underreporting of recurrence, and potential misclassification of treatments. The study's strengths include the use of real-world data from 70,000 NSCLC patients in the VONKOdb. The study was supported by Bristol Myers Squibb, and professional writing and editorial assistance were provided by Parexel.

Asset Subtitle

Melinda J Daumont

Meta Tag

Speaker Melinda J Daumont

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

real-world data

VONKOdb

disease-free survival

NSCLC

surgery

adjuvant therapy

perioperative therapy

baseline

immunotherapy

patient management